https://finance.yahoo.com/news/egf-theramed-health-closes-joint-123000645.html
the Agreement, the parties will collaborate at the Company's lab facilities in Nevada, for the further development and commercial
exploitation of certain of Pharmadelic Lab's intellectual property focused on creating biosynthesis pathways for psilocybin.
The Company further reports that Jeff Lipton, Chief Financial Officer of Pharmadelic Labs, has joined the Board of Directors of the Company.
Mr. Lipton has practiced corporate, tax and securities law for over three decades and was called to the Bar in the UK and Canada.
He also has an MBA and is a CFA. Mr. Lipton has held posts as a regulator, manager, investment banker and senior executive across a wide and diversified group of companies and industries.
With extensive experience in capital markets and technology, he lends managerial capacity and credibility to corporate endeavors.
George Anstey, Chief Executive Officer of Pharmadelic Labs stated, "We are excited that EGF Theramed Health recognizes the huge potential of the psilocybin market in treating mental health.
We look forward to collaborating on innovative processes using synthetic DNA taken from mushrooms to produce a final product that will be made quicker, cheaper, and of a higher and more consistent quality than growing the product under traditional production methods."
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM